ClinicalTrials.gg
Not yet recruitingNCT07659106DECIDE-VTEUpdated Jun 24, 2026

Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism

An interventional study of DECIDE-VTE Patient Decision Aid in Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) and Pulmonary Embolism, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Not yet recruiting at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 118 studies in Venous Thromboembolism with a site in Canada — 13 open to participants now, 13 under way, 8 of them phase 3. Venous Thromboembolism · Canada.

Planned enrollment
40th of 98
850 · median 506
Started
2026
with 2 others
No phase
6 of 118
1 open now
Primary completion
2028-03
later than 6 of 12 live
Registered
118th of 118
by date

Among the 118 studies in Venous Thromboembolism with a site in Canada, this one is the 40th largest by planned enrollment of the 98 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 118th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

13 of the 118 studies in Venous Thromboembolism with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Venous Thromboembolism with a site in Canada, or all of them as a file.
02

Study summary

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants). After completing at least 3 months of treatment for a first unprovoked or weakly provoked VTE, patients and clinicians must decide whether to stop anticoagulation or continue treatment for a longer period. Continuing anticoagulation reduces the risk of another blood clot but increases the risk of bleeding. Because both options involve important benefits and risks, this decision should reflect the patient's values and preferences.

The DECIDE-VTE study will evaluate whether a patient decision aid can improve decision-making for patients facing this choice. The decision aid provides evidence-based information about the risks and benefits of continuing versus stopping anticoagulation and includes a values clarification exercise to help patients identify what matters most to them.

This multicentre batched stepped-wedge cluster randomized trial will be conducted in 12 thrombosis clinics across Canada. Clinics will transition from usual care to implementation of the patient decision aid according to a randomized schedule. The primary outcome is decisional conflict immediately following the anticoagulation decision visit, measured using the Decisional Conflict Scale. Secondary outcomes include patient knowledge, treatment decisions, decisional regret, concordance with the chosen treatment strategy, recurrent venous thromboembolism, major bleeding, all-cause mortality, and implementation outcomes.

Read the detailed description

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is commonly treated with anticoagulation. After completing initial anticoagulation for a first unprovoked or weakly provoked VTE, patients and clinicians must decide whether to discontinue anticoagulation or continue treatment long term. This is a preference-sensitive decision because continued anticoagulation reduces the risk of recurrent VTE but increases the risk of bleeding.

The DECIDE-VTE Patient Decision Aid was developed to support shared decision-making about anticoagulation duration. The tool provides structured information about treatment options, recurrence and bleeding risks, and includes a values-clarification exercise to help patients consider which outcomes and treatment burdens matter most to them.

This study is a pragmatic, multicentre, batched stepped-wedge cluster randomized trial. Participating thrombosis clinics begin in the usual care phase and transition to implementation of the DECIDE-VTE Patient Decision Aid according to a randomized schedule. Randomization occurs at the clinic level to reduce contamination between study conditions and to reflect real-world implementation of the decision aid into routine thrombosis clinic care.

The study will assess whether integrating the DECIDE-VTE Patient Decision Aid into clinical care improves decision quality compared with usual care, and will also evaluate implementation-related measures relevant to future use of the tool in practice.

03

Conditions studied

  • Venous Thromboembolism (VTE)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism

Keywords

  • Anticoagulation
  • Patient Decision Aid
  • Shared Decision Making
  • Extended Anticoagulation
  • Decisional Conflict
  • Stepped-Wedge Cluster Randomized Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • First episode of objectively confirmed unprovoked or weakly provoked venous thromboembolism (VTE)
  • Objectively confirmed proximal deep vein thrombosis and/or segmental or greater pulmonary embolism
  • Completed at least 3 months of therapeutic anticoagulation and currently receiving anticoagulation
  • Enrollment within 12 months of diagnosis of the index/qualifying VTE event
  • Able to provide written
  • Able to participate in shared decision-making in English or French

Exclusion criteria

Exclusion Criteria:

  • Recurrent unprovoked or weakly provoked VTE I(i.e. multiple unprovoked/weakly provoked VTE)
  • Index/qualifying VTE is a strongly provoked VTE (e.g., associated with major surgery, major trauma, plaster cast immobilization, or prolonged bed rest)
  • Index/qualifying VTE associated with a persistent strong provoking risk factor (e.g., active cancer or ongoing immobility)
  • Women at very low recurrence risk (HERDOO2 score 0-1)
  • High bleeding risk such that anticoagulation should be discontinued
  • Requirement for long-term anticoagulation for another indication (e.g., atrial fibrillation)
  • Prior dedicated long-term anticoagulation Decision Visit regarding anticoagulation duration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Participants receive standard thrombosis clinic care and clinician-patient discussions regarding continuation versus discontinuation of anticoagulation following a first unprovoked or weakly provoked venous thromboembolism. No structured patient decision aid is used.

  • Experimental
    DECIDE-VTE Patient Decision Aid

    Participants receive the DECIDE-VTE Patient Decision Aid in addition to usual thrombosis clinic care. The decision aid provides evidence-based information regarding the risks and benefits of continuing versus discontinuing anticoagulation after a first unprovoked or weakly provoked venous thromboembolism and includes a structured values clarification exercise to support shared decision-making. Participants and clinicians make the final treatment decision together during the Decision Visit.

    Behavioral: DECIDE-VTE Patient Decision Aid

Interventions

  • BehavioralDECIDE-VTE Patient Decision Aid

    The DECIDE-VTE Patient Decision Aid is a bilingual (English/French) evidence-based decision support tool designed for adults with a first unprovoked or weakly provoked venous thromboembolism who are deciding whether to continue or discontinue anticoagulation after completing at least 3 months of therapy. The decision aid presents balanced information regarding the risks and benefits of extended anticoagulation, including risks of recurrent venous thromboembolism and major bleeding, and incorporates a structured values clarification exercise to support shared decision-making between patients and clinicians during the anticoagulation Decision Visit.

06

What researchers measure

Primary outcomes

  1. Decisional Conflict Scale (DCS) Total Score

    Decisional conflict measured using the validated 16-item Decisional Conflict Scale (DCS). Total scores range from 0 to 100, with higher scores indicating greater decisional conflict.

    Time frame: Decision Visit (Day 0)

Secondary outcomes

  1. VTE Knowledge Assessment Score

    Patient knowledge regarding recurrent venous thromboembolism and bleeding risks assessed using a 6-item true/false questionnaire. Scores range from 0 to 6, with higher scores indicating greater knowledge.

    Time frame: Decision Visit (Day 0)

  2. Treatment Decision

    Patient decision regarding continuation versus discontinuation of anticoagulation therapy.

    Time frame: Decision Visit (Day 0)

  3. Decisional Regret Scale (DRS) Score

    Decisional regret measured using the validated 5-item Decisional Regret Scale (DRS). Scores range from 0 to 100, with higher scores indicating greater regret regarding the treatment decision.

    Time frame: 3-Month Follow-Up Visit (Day 90 ± 14 days)

  4. Concordance With Treatment Decision

    Agreement between the treatment decision made at the Decision Visit (Day 0) and participant-reported anticoagulant use status at follow-up.

    Time frame: 3-Month Follow-Up Visit (Day 90 ± 14 days) and 12-Month Follow-Up Visit (Day 365 ± 60 days)

  5. Recurrent Venous Thromboembolism

    Adjudicated objectively confirmed recurrent venous thromboembolism assessed using the INVENT VERDICT adjudication process.

    Time frame: 12-Month Follow-Up Visit (Day 365 ± 60 days)

  6. Major Bleeding

    Adjudicated objectively confirmed major bleeding defined according to International Society on Thrombosis and Haemostasis criteria.

    Time frame: 12-Month Follow-Up Visit (Day 365 ± 60 days)

  7. All-Cause Mortality

    Death from any cause identified through medical record review and, where necessary, provincial vital statistics records.

    Time frame: 12-Month Follow-Up Visit (Day 365 ± 60 days)

Other outcomes

  1. Patient Decision Aid Use Time

    Time in minutes spent interacting with the DECIDE-VTE Patient Decision Aid.

    Time frame: Decision Visit (Day 0)

  2. Physician Visit Duration

    Time in minutes from the participant entering the clinic room with the physician until completion of the clinical encounter.

    Time frame: Decision Visit (Day 0)

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: TBD near end of follow-up of last participant

Access criteria: contact study PI

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.

Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 18 months is below that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 22, 2026
StartEst.
Sep 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07659106
Responsible party
Marc Rodger (Professor, Department of Medicine, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jun 22, 2026
Start date
Sep 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Harika Dasari
Contact
harika.dasari@rimuhc.ca
5144319353
Marc Rodger, MD MSc FRCPC
principal investigator · McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion